Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biobusiness Briefs
  • Published:

Trial watch

Burgeoning oncology pipeline raises questions about sustainability

Nature Reviews Drug Discovery volume 17, pages 698–699 (2018)Cite this article

Subjects

With the rebound in annual new drug approval rates and groundbreaking advances including the immuno-oncology revolution and pioneering gene and cell therapies reaching patients, optimism about biopharma industry productivity has risen substantially in the past few years. However, in the light of the ongoing debate about how new therapeutics will be paid for, the long-term sustainability of the current output is likely to depend heavily on the ability of pipeline products to provide meaningful benefits over existing treatment options in order to justify reimbursement.

Oncology is clearly an area of major unmet need, with a strong substrate of research advances to translate into new therapeutics, which is driving companies to focus in the area. However, it must be questioned whether, for example, in non-Hodgkin lymphoma (NHL) how many of the ~30 NMEs that are modelled to eventually reach the market based on the 179 that are currently in clinical trials for NHL (Fig. 1b) have strong potential to offer meaningful benefit to patients, rather than incremental improvements in outcomes, particularly as the market becomes more crowded. If it is the latter, there is a substantial risk that many of the projects may be terminated at some point because of a lack of potential for meaningful clinical benefit and commercial viability. A similar question could be asked about many of the other top 15 indications in Fig. 1b, 11 of which are in oncology. More broadly, given the intense debate about drug prices and higher barriers to commercial success, this analysis supports the view that a wider focus — including more of the multitude of difficult-to-treat conditions beyond oncology as well as clearly demonstrating value to cost-constrained health-care systems — will be needed for productivity to be sustained in the longer term.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Therapeutic area focus of clinical-stage development programmes for new drugs.

Author information

Authors and Affiliations

  1. EvaluatePharma, London, UK

    Jon Moser & Paul Verdin

Authors
  1. Jon Moser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Verdin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jon Moser or Paul Verdin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Indication (XLSX 191 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moser, J., Verdin, P. Burgeoning oncology pipeline raises questions about sustainability. Nat Rev Drug Discov 17, 698–699 (2018). https://doi.org/10.1038/nrd.2018.165

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.165

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research